BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou F, Shang W, Yu X, Tian J. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med Res Rev. 2018;38:741-767. [PMID: 28621802 DOI: 10.1002/med.21455] [Cited by in Crossref: 87] [Cited by in F6Publishing: 100] [Article Influence: 17.4] [Reference Citation Analysis]
Number Citing Articles
1 Mahati S, Fu X, Ma X, Zhang H, Xiao L. Delivery of miR-26a Using an Exosomes-Based Nanosystem Inhibited Proliferation of Hepatocellular Carcinoma. Front Mol Biosci 2021;8:738219. [PMID: 34552961 DOI: 10.3389/fmolb.2021.738219] [Reference Citation Analysis]
2 Yu X, Ye Z, Hou L, Zhang X, Liu Z, Wu R, Huang F, Wang G, Geng X, Zhao H. Hepatitis B virus x gene-downregulated growth-arrest specific 5 inhibits the cell viability and invasion of hepatocellular carcinoma cell lines by activating Y-box-binding protein 1/p21 signaling. J Cell Commun Signal 2021. [PMID: 34535871 DOI: 10.1007/s12079-021-00645-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Han J, Thurnherr T, Chung AYF, Goh BKP, Chow PKH, Chan CY, Cheow PC, Lee SY, Lim TKH, Chong SS, Ooi LLPJ, Lee CG. Clinicopathological-Associated Regulatory Network of Deregulated circRNAs in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2772. [PMID: 34199580 DOI: 10.3390/cancers13112772] [Reference Citation Analysis]
4 Zhao J, Gao S, Sun W, Grimm R, Fu C, Han J, Sheng R, Zeng M. Magnetic resonance imaging and diffusion-weighted imaging-based histogram analyses in predicting glypican 3-positive hepatocellular carcinoma. Eur J Radiol 2021;139:109732. [PMID: 33905978 DOI: 10.1016/j.ejrad.2021.109732] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Liu SS, Liu YS, Guo XY, Murakami Y, Yang G, Gao XD, Kinoshita T, Fujita M. A knockout cell library of GPI biosynthetic genes for functional studies of GPI-anchored proteins. Commun Biol 2021;4:777. [PMID: 34162996 DOI: 10.1038/s42003-021-02337-1] [Reference Citation Analysis]
6 Lee SR, Lee JG, Heo JH, Jo SL, Ryu J, Kim G, Yon JM, Lee MS, Lee GS, An BS, Shin HJ, Woo DC, Baek IJ, Hong EJ. Loss of PGRMC1 Delays the Progression of Hepatocellular Carcinoma via Suppression of Pro-Inflammatory Immune Responses. Cancers (Basel) 2021;13:2438. [PMID: 34069911 DOI: 10.3390/cancers13102438] [Reference Citation Analysis]
7 Jin C, Li Y, Su Y, Guo Z, Wang X, Wang S, Zhang F, Zhang Z, Shao J, Zheng S. Novel copper complex CTB regulates methionine cycle induced TERT hypomethylation to promote HCC cells senescence via mitochondrial SLC25A26. Cell Death Dis 2020;11:844. [PMID: 33041323 DOI: 10.1038/s41419-020-03048-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
8 Huang J, Chen X, Zhu W. MRGBP is a potential novel prognostic biomarker and is correlated with immune infiltrates in hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e25234. [PMID: 33761715 DOI: 10.1097/MD.0000000000025234] [Reference Citation Analysis]
9 Chen Y, E CY, Gong ZW, Liu S, Wang ZX, Yang YS, Zhang XW. Chimeric antigen receptor-engineered T-cell therapy for liver cancer. Hepatobiliary Pancreat Dis Int. 2018;17:301-309. [PMID: 29861325 DOI: 10.1016/j.hbpd.2018.05.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
10 Zhang XX, Ni B, Li Q, Hu LP, Jiang SH, Li RK, Tian GA, Zhu LL, Li J, Zhang XL, Zhang YL, Yang XM, Yang Q, Wang YH, Zhu CC, Zhang ZG. GPAA1 promotes gastric cancer progression via upregulation of GPI-anchored protein and enhancement of ERBB signalling pathway. J Exp Clin Cancer Res 2019;38:214. [PMID: 31118109 DOI: 10.1186/s13046-019-1218-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Li YP, Wang WZ, Chen XQ, Li LB, Liang ZY, Ru K, Li JN. Signal Transducer and Activator of Transcription 3 for the Differentiation of Hepatocellular Carcinoma from Cirrhosis. Chin Med J (Engl) 2017;130:2686-90. [PMID: 29133756 DOI: 10.4103/0366-6999.218016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
12 Karimi SS, Garzon S. Intraplacental Hepatic Heterotopia. Fetal Pediatr Pathol 2021;:1-5. [PMID: 33399014 DOI: 10.1080/15513815.2020.1865490] [Reference Citation Analysis]
13 Ma R, Zhao M, Zou X, Zhou J, Bai Z. MicroRNA polymorphism: A target for diagnosis and prognosis of hepatocellular carcinoma? Oncol Lett 2021;21:324. [PMID: 33692856 DOI: 10.3892/ol.2021.12586] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Wang P, Qin W, Liu T, Jiang D, Cui L, Liu X, Fang Y, Tang X, Jin H, Qian Q. PiggyBac-engineered T cells expressing a glypican-3-specific chimeric antigen receptor show potent activities against hepatocellular carcinoma. Immunobiology 2020;225:151850. [PMID: 31522780 DOI: 10.1016/j.imbio.2019.09.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
15 Dituri F, Gigante G, Scialpi R, Mancarella S, Fabregat I, Giannelli G. Proteoglycans in Cancer: Friends or Enemies? A Special Focus on Hepatocellular Carcinoma. Cancers 2022;14:1902. [DOI: 10.3390/cancers14081902] [Reference Citation Analysis]
16 Yang S, Cai C, Wang H, Ma X, Shao A, Sheng J, Yu C. Drug delivery strategy in hepatocellular carcinoma therapy. Cell Commun Signal 2022;20. [DOI: 10.1186/s12964-021-00796-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Zhong L, Huang Y, He J, Yang N, Xu B, Ma Y, Liu J, Tang C, Luo C, Wu P, Lai Z, Huo Y, Lu T, Huang D, Gong W, Gan L, Luo Y, Zhang Z, Liu X, Zhao Y. Generation of in situ CRISPR-mediated primary and metastatic cancer from monkey liver. Signal Transduct Target Ther 2021;6:411. [PMID: 34857736 DOI: 10.1038/s41392-021-00799-7] [Reference Citation Analysis]
18 Colli A, Nadarević T, Miletić D, Giljaca V, Fraquelli M, Štimac D, Casazza G; Cochrane Hepato-Biliary Group. Abdominal ultrasound and alpha-fetoprotein for the diagnosis of hepatocellular carcinoma. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013346] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
19 Dong W, Yan K, Yu H, Huo L, Xian Z, Zhao Y, Li J, Zhang Y, Cao Z, Fu Y, Cong W, Dong H. Prognostic Nomogram for Sorafenib Benefit in Hepatitis B Virus-Related Hepatocellular Carcinoma After Partial Hepatectomy. Front Oncol 2020;10:605057. [PMID: 33643907 DOI: 10.3389/fonc.2020.605057] [Reference Citation Analysis]
20 Liu K, Duan J, Liu H, Yang X, Yang J, Wu M, Chang Y. Precancer antiviral treatment reduces microvascular invasion of early-stage Hepatitis B-related hepatocellular carcinoma. Sci Rep 2019;9:2220. [PMID: 30778112 DOI: 10.1038/s41598-019-39440-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
21 Wang X, Wu F, Li G, Zhang N, Song X, Zheng Y, Gong C, Han B, He G. Lipid-modified cell-penetrating peptide-based self-assembly micelles for co-delivery of narciclasine and siULK1 in hepatocellular carcinoma therapy. Acta Biomater 2018;74:414-29. [PMID: 29787814 DOI: 10.1016/j.actbio.2018.05.030] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
22 Zhang Y, Wang Y. Circular RNAs in Hepatocellular Carcinoma: Emerging Functions to Clinical Significances. Front Oncol 2021;11:667428. [PMID: 34055634 DOI: 10.3389/fonc.2021.667428] [Reference Citation Analysis]
23 Xu H, Tang Y, Zhao Y, Wang F, Gao X, Deng D, Gu Y. SPECT Imaging of Hepatocellular Carcinoma Detection by the GPC3 Receptor. Mol Pharm 2021;18:2082-90. [PMID: 33797932 DOI: 10.1021/acs.molpharmaceut.1c00060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Di H, Mi Z, Sun Y, Liu X, Liu X, Li A, Jiang Y, Gao H, Rong P, Liu D. Nanozyme-assisted sensitive profiling of exosomal proteins for rapid cancer diagnosis. Theranostics 2020;10:9303-14. [PMID: 32802193 DOI: 10.7150/thno.46568] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
25 Brown ZJ, Hewitt DB, Pawlik TM. Experimental drug treatments for hepatocellular carcinoma: Clinical trial failures 2015 to 2021. Expert Opin Investig Drugs 2022. [PMID: 35580650 DOI: 10.1080/13543784.2022.2079491] [Reference Citation Analysis]
26 Chen P, Jiang P, Lin Q, Zeng X, Liu T, Li M, Yuan Y, Song S, Zhang J, Huang J, Ying B, Chen J. Simultaneous Homogeneous Fluorescence Detection of AFP and GPC3 in Hepatocellular Carcinoma Clinical Samples Assisted by Enzyme-Free Catalytic Hairpin Assembly. ACS Appl Mater Interfaces 2022. [PMID: 35699181 DOI: 10.1021/acsami.2c09135] [Reference Citation Analysis]
27 Mocan T, Simão AL, Castro RE, Rodrigues CMP, Słomka A, Wang B, Strassburg C, Wöhler A, Willms AG, Kornek M. Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning? J Clin Med 2020;9:E1541. [PMID: 32443747 DOI: 10.3390/jcm9051541] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
28 Ruman U, Fakurazi S, Masarudin MJ, Hussein MZ. Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities. Int J Nanomedicine 2020;15:1437-56. [PMID: 32184597 DOI: 10.2147/IJN.S236927] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
29 Roddy H, Meyer T, Roddie C. Novel Cellular Therapies for Hepatocellular Carcinoma. Cancers (Basel) 2022;14:504. [PMID: 35158772 DOI: 10.3390/cancers14030504] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
30 Chu Q, Mu W, Lan C, Liu Y, Gao T, Guan L, Fang Y, Zhang Z, Liu Y, Liu Y, Zhang N. High-Specific Isolation and Instant Observation of Circulating Tumour Cell from HCC Patients via Glypican-3 Immunomagnetic Fluorescent Nanodevice. Int J Nanomedicine 2021;16:4161-73. [PMID: 34168446 DOI: 10.2147/IJN.S307691] [Reference Citation Analysis]
31 Lu Q, Long Y, Fan K, Shen Z, Gai Y, Liu Q, Jiang D, Cai W, Wan C, Lan X. PET imaging of hepatocellular carcinoma by targeting tumor-associated endothelium using [68Ga]Ga-PSMA-617. Eur J Nucl Med Mol Imaging 2022. [PMID: 35763056 DOI: 10.1007/s00259-022-05884-9] [Reference Citation Analysis]
32 Wang W, Wei C. Advances in the early diagnosis of hepatocellular carcinoma. Genes Dis 2020;7:308-19. [PMID: 32884985 DOI: 10.1016/j.gendis.2020.01.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
33 Yu L, Yang X, Huang N, Lang QL, He QL, Jian-Hua W, Liang-Peng G. A novel targeted GPC3/CD3 bispecific antibody for the treatment hepatocellular carcinoma. Cancer Biol Ther. 2020;21:597-603. [PMID: 32240054 DOI: 10.1080/15384047.2020.1743158] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Atay S. Evaluation of tumoral glypican 3 mRNA level as a diagnostic and prognostic biomarker for hepatitis-b virus-associated hepatocellular carcinoma by an integrative transcriptomic meta-analysis and bioinformatics. ETD. [DOI: 10.19161/etd.1127225] [Reference Citation Analysis]
35 Yao M, Yang JL, Wang DF, Wang L, Chen Y, Yao DF. Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma. World J Clin Cases 2022; 10(11): 3321-3333 [DOI: 10.12998/wjcc.v10.i11.3321] [Reference Citation Analysis]
36 Lian Q, Wang S, Zhang G, Wang D, Luo G, Tang J, Chen L, Gu J. HCCDB: A Database of Hepatocellular Carcinoma Expression Atlas. Genomics Proteomics Bioinformatics. 2018;16:269-275. [PMID: 30266410 DOI: 10.1016/j.gpb.2018.07.003] [Cited by in Crossref: 57] [Cited by in F6Publishing: 69] [Article Influence: 14.3] [Reference Citation Analysis]
37 Li S, Zhang Y, Liu X, Tian Y, Cheng Y, Tang L, Lin H. Smart NIR-II croconaine dye-peptide for enhanced photo-sonotheranostics of hepatocellular carcinoma. Theranostics 2022;12:76-86. [PMID: 34987635 DOI: 10.7150/thno.64759] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
38 Chen R, Bai Y, Liu T, Zhang G, Han Y, Chen L, Gao H, Wei W, Wang M. Evaluation of Glypican-3 Expression in Hepatocellular Carcinoma by Using IDEAL IQ Magnetic Resonance Imaging. Acad Radiol 2021;28:e227-34. [PMID: 32540197 DOI: 10.1016/j.acra.2020.05.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Yan J, Yu X, Chen X, Liu F, Chen F, Ding N, Yu L, Meng F, Shen J, Wei J, Liu B. Identification of a Glypican-3 Binding Peptide From a Phage-Displayed Peptide Library for PET Imaging of Hepatocellular Carcinoma. Front Oncol 2021;11:679336. [PMID: 34150644 DOI: 10.3389/fonc.2021.679336] [Reference Citation Analysis]
40 Lanzi C, Cassinelli G. Receptor tyrosine kinases and heparan sulfate proteoglycans: Interplay providing anticancer targeting strategies and new therapeutic opportunities. Biochemical Pharmacology 2020;178:114084. [DOI: 10.1016/j.bcp.2020.114084] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
41 Meier T, Timm M, Montani M, Wilkens L. Gene networks and transcriptional regulators associated with liver cancer development and progression. BMC Med Genomics 2021;14:41. [PMID: 33541355 DOI: 10.1186/s12920-021-00883-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Liu X, Wen J, Yi H, Hou X, Yin Y, Ye G, Wu X, Jiang X. Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release. Ther Adv Med Oncol. 2020;12:1758835920910347. [PMID: 32215059 DOI: 10.1177/1758835920910347] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
43 Luo XY, Wu KM, He XX. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. J Exp Clin Cancer Res 2021;40:172. [PMID: 34006331 DOI: 10.1186/s13046-021-01968-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
44 Ye Z, Qian Q, Jin H, Qian Q. Cancer vaccine: learning lessons from immune checkpoint inhibitors. J Cancer 2018;9:263-8. [PMID: 29344272 DOI: 10.7150/jca.20059] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
45 Lao Z, Li S, Liang J, Su J, Gong X, Cui X, Zhao S. Production and characterization of GPC3-N protein and its nanobody. Protein Expression and Purification 2022. [DOI: 10.1016/j.pep.2022.106094] [Reference Citation Analysis]
46 Irshad K, Malik N, Arora M, Gupta Y, Sinha S, Chosdol K. The quest for ligands and binding partners of atypical cadherin FAT1. Transl Oncol 2021;14:101097. [PMID: 33878524 DOI: 10.1016/j.tranon.2021.101097] [Reference Citation Analysis]
47 Li J, Yan S. MiR-466 Inhibits the Progression of Severe Hepatocellular Carcinoma via Regulating FMNL2-Mediated Activation of NF-κB and Wnt/β-Catenin Pathways. J Oncol 2021;2021:3554219. [PMID: 34257650 DOI: 10.1155/2021/3554219] [Reference Citation Analysis]
48 Burenina OY, Lazarevich NL, Kustova IF, Shavochkina DA, Moroz EA, Kudashkin NE, Patyutko YI, Metelin AV, Kim EF, Skvortsov DA, Zatsepin TS, Rubtsova MP, Dontsova OA. Panel of potential lncRNA biomarkers can distinguish various types of liver malignant and benign tumors. J Cancer Res Clin Oncol 2021;147:49-59. [PMID: 32918630 DOI: 10.1007/s00432-020-03378-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
49 Juengpanich S, Topatana W, Lu C, Staiculescu D, Li S, Cao J, Lin J, Hu J, Chen M, Chen J, Cai X. Role of cellular, molecular and tumor microenvironment in hepatocellular carcinoma: Possible targets and future directions in the regorafenib era. Int J Cancer 2020;147:1778-92. [PMID: 32162677 DOI: 10.1002/ijc.32970] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
50 Guo J, Tang Q. Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma. Cancer Gene Ther. 2021;. [PMID: 33500535 DOI: 10.1038/s41417-020-00259-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
51 Guo M, Zhang H, Zheng J, Liu Y. Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma. J Cancer. 2020;11:2008-2021. [PMID: 32127929 DOI: 10.7150/jca.39972] [Cited by in Crossref: 22] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
52 Sun W, Hu C, Wang T, Wang J, Zhang J, Gao F, Ou Q, Tian H, Jin C, Xu J, Zhang J, Xu GT, Lu L. Glia Maturation Factor Beta as a Novel Biomarker and Therapeutic Target for Hepatocellular Carcinoma. Front Oncol 2021;11:744331. [PMID: 34796110 DOI: 10.3389/fonc.2021.744331] [Reference Citation Analysis]
53 Feng S, Meng X, Li Z, Chang TS, Wu X, Zhou J, Joshi B, Choi EY, Zhao L, Zhu J, Wang TD. Multi-Modal Imaging Probe for Glypican-3 Overexpressed in Orthotopic Hepatocellular Carcinoma. J Med Chem 2021;64:15639-50. [PMID: 34590489 DOI: 10.1021/acs.jmedchem.1c00697] [Reference Citation Analysis]
54 Tong Y, Tong K, Zhu Q, Wu Y, Yang Y, Zhang J, Hu P, Yan S. Cobalt Chloride Induced Apoptosis by Inhibiting GPC3 Expression via the HIF-1α/c-Myc Axis in HepG2 Cells. Onco Targets Ther 2019;12:10663-70. [PMID: 31824173 DOI: 10.2147/OTT.S227215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Zhu Y, Cheung ALM. Proteoglycans and their functions in esophageal squamous cell carcinoma. World J Clin Oncol 2021; 12(7): 507-521 [PMID: 34367925 DOI: 10.5306/wjco.v12.i7.507] [Reference Citation Analysis]
56 Liu D, Luo Y, Chen L, Chen L, Zuo D, Li Y, Zhang X, Wu J, Xi Q, Li G, Qi L, Yue X, Zhang X, Sun Z, Zhang N, Song T, Lu W, Guo H. Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study. Cancer Biol Med 2021;18:256-70. [PMID: 33628599 DOI: 10.20892/j.issn.2095-3941.2020.0207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Gupta R, Kleinjans J, Caiment F. Identifying novel transcript biomarkers for hepatocellular carcinoma (HCC) using RNA-Seq datasets and machine learning. BMC Cancer 2021;21:962. [PMID: 34445986 DOI: 10.1186/s12885-021-08704-9] [Reference Citation Analysis]
58 Aydin Y, Koksal AR, Thevenot P, Chava S, Heidari Z, Lin D, Sandow T, Moroz K, Parsi MA, Scott J, Cohen A, Dash S. Experimental Validation of Novel Glypican 3 Exosomes for the Detection of Hepatocellular Carcinoma in Liver Cirrhosis. JHC 2021;Volume 8:1579-96. [DOI: 10.2147/jhc.s327339] [Reference Citation Analysis]
59 Damiris K, Abbad H, Pyrsopoulos N. Cellular based treatment modalities for unresectable hepatocellular carcinoma. World J Clin Oncol 2021; 12(5): 290-308 [PMID: 34131562 DOI: 10.5306/wjco.v12.i5.290] [Reference Citation Analysis]
60 Zhang W, Hu Z, Tian J, Fang C. A narrative review of near-infrared fluorescence imaging in hepatectomy for hepatocellular carcinoma. Ann Transl Med 2021;9:171. [PMID: 33569473 DOI: 10.21037/atm-20-5341] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Wei ZL, Zhou X, Lan CL, Huang HS, Liao XW, Mo ST, Wei YG, Peng T. Clinical implications and molecular mechanisms of Cyclin-dependent kinases 4 for patients with hepatocellular carcinoma. BMC Gastroenterol 2022;22:77. [PMID: 35193513 DOI: 10.1186/s12876-022-02152-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Shao L, Yu X, Han Q, Zhang X, Lu N, Zhang C. Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma. OncoImmunology 2022;11:2010894. [DOI: 10.1080/2162402x.2021.2010894] [Reference Citation Analysis]
63 Vaziri F, Colquhoun S, Wan YY. Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome. Liver Res 2020;4:191-8. [PMID: 33343967 DOI: 10.1016/j.livres.2020.10.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
64 Zhang Y, Zhao J, Cai J, Ye JC, Xiao YT, Mei Y, Zeng MS, Xie CM, Jiang Y, Feng GK. Integrin α6-Targeted Magnetic Resonance Imaging of Hepatocellular Carcinoma in Mice. Mol Imaging Biol 2020;22:864-72. [PMID: 31792839 DOI: 10.1007/s11307-019-01437-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Gong T, Ning X, Deng Z, Liu M, Zhou B, Chen X, Huang S, Xu Y, Chen Z, Luo R. Propofol‐induced miR‐219‐5p inhibits growth and invasion of hepatocellular carcinoma through suppression of GPC3‐mediated Wnt/β‐catenin signalling activation. J Cell Biochem 2019;120:16934-45. [DOI: 10.1002/jcb.28952] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
66 Lepedda AJ, Nieddu G, Piperigkou Z, Kyriakopoulou K, Karamanos N, Formato M. Circulating Heparan Sulfate Proteoglycans as Biomarkers in Health and Disease. Semin Thromb Hemost 2021;47:295-307. [PMID: 33794553 DOI: 10.1055/s-0041-1725063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
67 Guo X, Tian S, Cao P, Xie Y, Dong W. High Expression of PIGC Predicts Unfavorable Survival in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:211-22. [PMID: 33854986 DOI: 10.2147/JHC.S297601] [Reference Citation Analysis]
68 Abdelhameid MK, Zaki I, Mohammed MR, Mohamed KO. Design, synthesis, and cytotoxic screening of novel azole derivatives on hepatocellular carcinoma (HepG2 Cells). Bioorg Chem 2020;101:103995. [PMID: 32569897 DOI: 10.1016/j.bioorg.2020.103995] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
69 Wei X, Zheng W, Tian P, He Y, Liu H, Peng M, Li X, Liu X. Oncogenic hsa_circ_0091581 promotes the malignancy of HCC cell through blocking miR-526b from degrading c-MYC mRNA. Cell Cycle 2020;19:817-24. [PMID: 32116112 DOI: 10.1080/15384101.2020.1731945] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
70 Zhang Y, Lv J, Liu P, Zhao X, Chen K, Li Q, Nie L, Fang C. Contrast-Enhanced Multispectral Photoacoustic Imaging for Irregular Hepatectomy Navigation: A Pilot Study. ACS Biomater Sci Eng 2020;6:5874-85. [PMID: 33320552 DOI: 10.1021/acsbiomaterials.0c00921] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Pan Y, Chen H, Yu J. Biomarkers in Hepatocellular Carcinoma: Current Status and Future Perspectives. Biomedicines 2020;8:E576. [PMID: 33297335 DOI: 10.3390/biomedicines8120576] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
72 Xiong X, Xi J, Liu Q, Wang C, Jiang Z, Yue SY, Shi L, Rong Y. Co-expression of IL-7 and PH20 promote anti-GPC3 CAR-T tumour suppressor activity in vivo and in vitro. Liver Int 2021;41:1033-43. [PMID: 33347692 DOI: 10.1111/liv.14771] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
73 Khalifa YH, Mourad GM, Stephanos WM, Omar SA, Mehanna RA. Bone Marrow-Derived Mesenchymal Stem Cell Potential Regression of Dysplasia Associating Experimental Liver Fibrosis in Albino Rats. Biomed Res Int 2019;2019:5376165. [PMID: 31781620 DOI: 10.1155/2019/5376165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
74 Chen D, Lin X, Zhang C, An G, Li Z, Dong B, Shen L, Gao J, Zhang X. Activated Wnt signaling promotes growth and progression of AFP-producing gastric cancer in preclinical models. Cancer Manag Res 2019;11:1349-62. [PMID: 30809100 DOI: 10.2147/CMAR.S187219] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
75 Sheng LQ, Li JR, Qin H, Liu L, Zhang DD, Zhang Q, Huang ML, Li XL, Xu XY, Wei YN, Chen ZS, Luo H, Zhang JY, Zhou CH, Chen H, Chen ZG, Li FG, Li NF. Blood exosomal micro ribonucleic acid profiling reveals the complexity of hepatocellular carcinoma and identifies potential biomarkers for differential diagnosis. World J Gastrointest Oncol 2020; 12(10): 1195-1208 [PMID: 33133386 DOI: 10.4251/wjgo.v12.i10.1195] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Meng P, Zhang YF, Zhang W, Chen X, Xu T, Hu S, Liang X, Feng M, Yang X, Ho M. Identification of the atypical cadherin FAT1 as a novel glypican-3 interacting protein in liver cancer cells. Sci Rep 2021;11:40. [PMID: 33420124 DOI: 10.1038/s41598-020-79524-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
77 Zweerink S, Mesghenna S, Mueck V, Schulte S, Kuetting F, Quaas A, Goeser T, Nierhoff D. First evaluation of Neighbor of Punc E11 (NOPE) as a novel marker in human hepatocellular carcinoma. Cancer Biomark 2021;30:75-83. [PMID: 32986656 DOI: 10.3233/CBM-190819] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Mckiver B, Damaj MI, Sarkar D. Assessment of Current Gene Therapy Practices in Hepatocellular Carcinoma. GastrointestDisord 2020;2:469-80. [DOI: 10.3390/gidisord2040042] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
79 Chen G, Luo D, Zhong N, Li D, Zheng J, Liao H, Li Z, Lin X, Chen Q, Zhang C, Lu Y, Chan YT, Ren Q, Wang N, Feng Y. GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer. Front Immunol 2022;13:857308. [PMID: 35345673 DOI: 10.3389/fimmu.2022.857308] [Reference Citation Analysis]
80 Chen M, Li H, Su X, Wu R, Feng H, Shi X, Liang J, Chen J, Li G. Label-free electrochemical aptasensor based on reduced graphene oxide–hemin–chitosan nanocomposite for the determination of glypican-3. New J Chem 2021;45:8608-18. [DOI: 10.1039/d1nj00633a] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Liu X, Du Q, Tian C, Tang M, Jiang Y, Wang Y, Cao Y, Wang Z, Wang Z, Yang J, Li Y, Jiao X, Xie P. Discovery of CAPE derivatives as dual EGFR and CSK inhibitors with anticancer activity in a murine model of hepatocellular carcinoma. Bioorg Chem 2021;107:104536. [PMID: 33342565 DOI: 10.1016/j.bioorg.2020.104536] [Reference Citation Analysis]
82 Chen F, Wang J, Wu Y, Gao Q, Zhang S. Potential Biomarkers for Liver Cancer Diagnosis Based on Multi-Omics Strategy. Front Oncol 2022;12:822449. [DOI: 10.3389/fonc.2022.822449] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
83 Wang Y, He M, Li X, Chai J, Jiang Q, Peng C, He G, Huang W. Design, Synthesis, and Biological Evaluation of Pyrano[2,3-c]-pyrazole-Based RalA Inhibitors Against Hepatocellular Carcinoma. Front Chem 2021;9:700956. [PMID: 34869198 DOI: 10.3389/fchem.2021.700956] [Reference Citation Analysis]
84 Motawi TMK, Sadik NAH, Sabry D, Shahin NN, Fahim SA. rs2267531, a promoter SNP within glypican-3 gene in the X chromosome, is associated with hepatocellular carcinoma in Egyptians. Sci Rep 2019;9:6868. [PMID: 31053802 DOI: 10.1038/s41598-019-43376-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
85 Dai M, Li S, Qin X. Colorectal neoplasia differentially expressed: a long noncoding RNA with an imperative role in cancer. Onco Targets Ther 2018;11:3755-63. [PMID: 29988699 DOI: 10.2147/OTT.S162754] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
86 De Pasquale V, Pavone LM. Heparan Sulfate Proteoglycan Signaling in Tumor Microenvironment. Int J Mol Sci 2020;21:E6588. [PMID: 32916872 DOI: 10.3390/ijms21186588] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
87 Gerlza T, Trojacher C, Kitic N, Adage T, Kungl AJ. Development of Molecules Antagonizing Heparan Sulfate Proteoglycans. Semin Thromb Hemost 2021;47:316-32. [PMID: 33794555 DOI: 10.1055/s-0041-1725067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Zhu Y, Yue M, Guo T, Li F, Li Z, Yang D, Lin M. PEI-PEG-Coated Mesoporous Silica Nanoparticles Enhance the Antitumor Activity of Tanshinone IIA and Serve as a Gene Transfer Vector. Evid Based Complement Alternat Med 2021;2021:6756763. [PMID: 34790248 DOI: 10.1155/2021/6756763] [Reference Citation Analysis]
89 Liu Y, Zhang J, Chen Y, Sohel H, Ke X, Chen J, Li YX. The correlation and role analysis of COL4A1 and COL4A2 in hepatocarcinogenesis. Aging (Albany NY) 2020;12:204-23. [PMID: 31905170 DOI: 10.18632/aging.102610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
90 Wang W, Xu C, Wang H, Jiang C. Identification of nanobodies against hepatocellular carcinoma marker glypican-3. Mol Immunol 2021;131:13-22. [PMID: 33453658 DOI: 10.1016/j.molimm.2021.01.010] [Reference Citation Analysis]
91 Nie JH, Yang T, Li H, Ye HS, Zhong GQ, Li TT, Zhang C, Huang WH, Xiao J, Li Z, He JL, Du BL, Zhang Y, Liu J. Identification of GPC3 mutation and upregulation in a multidrug resistant osteosarcoma and its spheroids as therapeutic target. J Bone Oncol 2021;30:100391. [PMID: 34611509 DOI: 10.1016/j.jbo.2021.100391] [Reference Citation Analysis]
92 Shi H, Huttad LV, Tan M, Liu H, Chua M, Cheng Z, So S. NIR-II imaging of hepatocellular carcinoma based on a humanized anti-GPC3 antibody. RSC Med Chem 2022;13:90-7. [DOI: 10.1039/d1md00313e] [Reference Citation Analysis]
93 Zaki I, El-sayed EH, Radwan EM. Synthesis and Antiproliferative Activity of Some New Coumarin Derivatives Derived from 8-Hydroxycoumarin. Russ J Bioorg Chem 2021;47:514-23. [DOI: 10.1134/s106816202102028x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Colli A, Nadarevic T, Miletic D, Giljaca V, Fraquelli M, Štimac D, Casazza G. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev 2021;4:CD013346. [PMID: 33855699 DOI: 10.1002/14651858.CD013346.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
95 Liu Y, Di S, Shi B, Zhang H, Wang Y, Wu X, Luo H, Wang H, Li Z, Jiang H. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma. J Immunol 2019;203:198-207. [PMID: 31142602 DOI: 10.4049/jimmunol.1800033] [Cited by in F6Publishing: 48] [Reference Citation Analysis]
96 Yu L, Yang X, Huang N, Wu M, Sun H, He Q, Lang Q, Zou X, Liu Z, Wang J, Ge L. Generation of fully human anti-GPC3 antibodies with high-affinity recognition of GPC3 positive tumors. Invest New Drugs 2021;39:615-26. [PMID: 33215325 DOI: 10.1007/s10637-020-01033-x] [Reference Citation Analysis]
97 Zhang C, Wang N, Tan HY, Guo W, Chen F, Zhong Z, Man K, Tsao SW, Lao L, Feng Y. Direct inhibition of the TLR4/MyD88 pathway by geniposide suppresses HIF-1α-independent VEGF expression and angiogenesis in hepatocellular carcinoma. Br J Pharmacol 2020;177:3240-57. [PMID: 32144747 DOI: 10.1111/bph.15046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
98 Li Y, Zhang J, Gu J, Hu K, Huang S, Conti PS, Wu H, Chen K. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma. Mol Imaging Biol 2020;22:134-43. [PMID: 31044341 DOI: 10.1007/s11307-019-01356-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
99 Pang YY, Li JD, Gao L, Yang X, Dang YW, Lai ZF, Liu LM, Yang J, Wu HY, He RQ, Huang ZG, Xiong DD, Yang LH, Shi L, Mo WJ, Tang D, Lu HP, Chen G. The clinical value and potential molecular mechanism of the downregulation of MAOA in hepatocellular carcinoma tissues. Cancer Med 2020;9:8004-19. [PMID: 32931665 DOI: 10.1002/cam4.3434] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
100 Ufuk A, Garner T, Stevens A, Latif A. Monocarboxylate Transporters Are Involved in Extracellular Matrix Remodelling in Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2022;14:1298. [PMID: 35267606 DOI: 10.3390/cancers14051298] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Tan AT, Schreiber S. Adoptive T-cell therapy for HBV-associated HCC and HBV infection. Antiviral Research 2020;176:104748. [DOI: 10.1016/j.antiviral.2020.104748] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
102 Deng H, Shang W, Lu G, Guo P, Ai T, Fang C, Tian J. Targeted and Multifunctional Technology for Identification between Hepatocellular Carcinoma and Liver Cirrhosis. ACS Appl Mater Interfaces 2019;11:14526-37. [PMID: 30776888 DOI: 10.1021/acsami.8b20600] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
103 Deng H, Shang W, Wang K, Guo K, Liu Y, Tian J, Fang C. Targeted-detection and sequential-treatment of small hepatocellular carcinoma in the complex liver environment by GPC-3-targeted nanoparticles. J Nanobiotechnology 2022;20:156. [PMID: 35331259 DOI: 10.1186/s12951-022-01378-w] [Reference Citation Analysis]
104 Brassart-Pasco S, Brézillon S, Brassart B, Ramont L, Oudart JB, Monboisse JC. Tumor Microenvironment: Extracellular Matrix Alterations Influence Tumor Progression. Front Oncol 2020;10:397. [PMID: 32351878 DOI: 10.3389/fonc.2020.00397] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 17.0] [Reference Citation Analysis]
105 Yan Q, Sun Y, An R, Liu F, Fang Q, Wang Z, Xu T, Chen L, Du J. Application and progress of the detection technologies in hepatocellular carcinoma. Genes & Diseases 2022. [DOI: 10.1016/j.gendis.2022.04.003] [Reference Citation Analysis]
106 Guo X, Wang Z, Deng X, Lu Y, Huang X, Lin J, Lan X, Su Q, Wang C. Circular RNA CircITCH (has-circ-0001141) suppresses hepatocellular carcinoma (HCC) progression by sponging miR-184. Cell Cycle. [DOI: 10.1080/15384101.2022.2057633] [Reference Citation Analysis]
107 Li G, Feng H, Shi X, Chen M, Liang J, Zhou Z. Highly sensitive electrochemical aptasensor for Glypican-3 based on reduced graphene oxide-hemin nanocomposites modified on screen-printed electrode surface. Bioelectrochemistry 2021;138:107696. [PMID: 33254049 DOI: 10.1016/j.bioelechem.2020.107696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
108 Xing M, Wang X, Kiken RA, He L, Zhang JY. Immunodiagnostic Biomarkers for Hepatocellular Carcinoma (HCC): The First Step in Detection and Treatment. Int J Mol Sci 2021;22:6139. [PMID: 34200243 DOI: 10.3390/ijms22116139] [Reference Citation Analysis]
109 Mossenta M, Busato D, Dal Bo M, Toffoli G. Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies. Cancers (Basel) 2020;12:E1668. [PMID: 32585931 DOI: 10.3390/cancers12061668] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
110 Gümüş Güler B, Özler S. Increased syndecan-1 and glypican-3 predict poor perinatal outcome and treatment resistance in intrahepatic cholestasis. Hepatobiliary Pancreat Dis Int 2020;19:271-6. [PMID: 31919038 DOI: 10.1016/j.hbpd.2019.12.001] [Reference Citation Analysis]
111 Zhang Q, Wang J, Liu M, Zhu Q, Li Q, Xie C, Han C, Wang Y, Gao M, Liu J. Weighted correlation gene network analysis reveals a new stemness index-related survival model for prognostic prediction in hepatocellular carcinoma. Aging (Albany NY) 2020;12:13502-17. [PMID: 32644941 DOI: 10.18632/aging.103454] [Reference Citation Analysis]
112 Chen Y, Yang W, Chen Q, Liu Q, Liu J, Zhang Y, Li B, Li D, Nan J, Li X, Wu H, Xiang X, Peng Y, Wang J, Su S, Wang Z. Prediction of hepatocellular carcinoma risk in patients with chronic liver disease from dynamic modular networks. J Transl Med 2021;19:122. [PMID: 33757544 DOI: 10.1186/s12967-021-02791-9] [Reference Citation Analysis]
113 Liu Z, Liu X, Liang J, Liu Y, Hou X, Zhang M, Li Y, Jiang X. Immunotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects. Front Immunol 2021;12:765101. [PMID: 34675942 DOI: 10.3389/fimmu.2021.765101] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Zou F, Tan J, Liu T, Liu B, Tang Y, Zhang H, Li J. The CD39+ HBV surface protein-targeted CAR-T and personalized tumor-reactive CD8+ T cells exhibit potent anti-HCC activity. Mol Ther 2021;29:1794-807. [PMID: 33484968 DOI: 10.1016/j.ymthe.2021.01.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
115 Yu W, Ma Y, Shrivastava SK, Srivastava RK, Shankar S. Chronic alcohol exposure induces hepatocyte damage by inducing oxidative stress, SATB2 and stem cell‐like characteristics, and activating lipogenesis. J Cellular Molecular Medi. [DOI: 10.1111/jcmm.17235] [Reference Citation Analysis]
116 Cao W, Sharma M, Imam R, Yu J. Study on Diagnostic Values of Astrocyte Elevated Gene 1 (AEG-1) and Glypican 3 (GPC-3) in Hepatocellular Carcinoma. Am J Clin Pathol 2019;152:647-55. [PMID: 31305883 DOI: 10.1093/ajcp/aqz086] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
117 Lai X, Wu Y, Hong G, Li J, Luo Q, Yuan J, Dai G, Liu S, Feng H, Wang F. A Novel Gene Signature Based on CDC20 and FCN3 for Prediction of Prognosis and Immune Features in Patients with Hepatocellular Carcinoma. Journal of Immunology Research 2022;2022:1-15. [DOI: 10.1155/2022/9117205] [Reference Citation Analysis]
118 Owusu Sekyere S, Schlevogt B, Mettke F, Kabbani M, Deterding K, Wirth TC, Vogel A, Manns MP, Falk CS, Cornberg M, Wedemeyer H. HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection. Liver Cancer 2019;8:41-65. [PMID: 30815394 DOI: 10.1159/000490360] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
119 Schobert IT, Savic LJ. Current Trends in Non-Invasive Imaging of Interactions in the Liver Tumor Microenvironment Mediated by Tumor Metabolism. Cancers (Basel) 2021;13:3645. [PMID: 34359547 DOI: 10.3390/cancers13153645] [Reference Citation Analysis]
120 Yao G, Yin J, Wang Q, Dong R, Lu J. Glypican-3 Enhances Reprogramming of Glucose Metabolism in Liver Cancer Cells. Biomed Res Int 2019;2019:2560650. [PMID: 31781603 DOI: 10.1155/2019/2560650] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
121 Zhou Z, Zhao L, Li W, Chen M, Feng H, Shi X, Liang J, Li G. Glypican-3 electrochemical aptamer nanobiosensor based on hemin/graphene nanohybrids peroxidase-like catalytic silver deposition. Mikrochim Acta 2020;187:305. [PMID: 32356075 DOI: 10.1007/s00604-020-04284-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
122 Zhu J, Wang Y, Yang P, Liu Q, Hu J, Yang W, Liu P, He F, Bai Y, Gai S, Xie R, Li C. GPC3-targeted and curcumin-loaded phospholipid microbubbles for sono-photodynamic therapy in liver cancer cells. Colloids and Surfaces B: Biointerfaces 2021;197:111358. [DOI: 10.1016/j.colsurfb.2020.111358] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
123 Nomura K, Kitanaka A, Iwama H, Tani J, Nomura T, Nakahara M, Ohura K, Tadokoro T, Fujita K, Mimura S, Yoneyama H, Kobara H, Morishita A, Okano K, Suzuki Y, Tsutsi K, Himoto T, Masaki T. Association between microRNA-527 and glypican-3 in hepatocellular carcinoma. Oncol Lett 2021;21:229. [PMID: 33613718 DOI: 10.3892/ol.2021.12490] [Reference Citation Analysis]
124 Dong L, Zhou H, Zhao M, Gao X, Liu Y, Liu D, Guo W, Hu H, Xie Q, Fan J, Lin J, Wu W. Phosphorothioate-Modified AP613-1 Specifically Targets GPC3 when Used for Hepatocellular Carcinoma Cell Imaging. Mol Ther Nucleic Acids 2018;13:376-86. [PMID: 30347351 DOI: 10.1016/j.omtn.2018.09.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
125 Qin Y, Cheng S, Li Y, Zou S, Chen M, Zhu D, Gao S, Wu H, Zhu L, Zhu X. The development of a Glypican-3-specific binding peptide using in vivo and in vitro two-step phage display screening for the PET imaging of hepatocellular carcinoma. Biomater Sci 2020;8:5656-65. [PMID: 32896851 DOI: 10.1039/d0bm00943a] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
126 Faria-Ramos I, Poças J, Marques C, Santos-Antunes J, Macedo G, Reis CA, Magalhães A. Heparan Sulfate Glycosaminoglycans: (Un)Expected Allies in Cancer Clinical Management. Biomolecules 2021;11:136. [PMID: 33494442 DOI: 10.3390/biom11020136] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
127 Shi X, Chen M, Feng H, Zhou Z, Wu R, Li W, Liang J, Chen J, Li G. Glypican-3 electrochemical aptasensor based on reduced graphene oxide‐chitosan‐ferrocene deposition of platinum–palladium bimetallic nanoparticles. J Appl Electrochem 2021;51:781-94. [DOI: 10.1007/s10800-021-01534-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
128 Xie HN, Chen YY, Zhu GB, Han HH, Hu XL, Pan ZQ, Zang Y, Xie DH, He XP, Li J, James TD. Targeted delivery of maytansine to liver cancer cells via galactose-modified supramolecular two-dimensional glycomaterial. Chem Commun (Camb) 2022;58:5029-32. [PMID: 35373789 DOI: 10.1039/d1cc06809a] [Reference Citation Analysis]
129 Kong Y, Chen H, Chen M, Li Y, Li J, Liu Q, Xiong H, Guo T, Xie Y, Yuan Y, Zhang XL. Abnormal ECA-Binding Membrane Glycans and Galactosylated CAT and P4HB in Lesion Tissues as Potential Biomarkers for Hepatocellular Carcinoma Diagnosis. Front Oncol 2022;12:855952. [PMID: 35392238 DOI: 10.3389/fonc.2022.855952] [Reference Citation Analysis]
130 Winkler S, Winkler I, Figaschewski M, Tiede T, Nordheim A, Kohlbacher O. De novo identification of maximally deregulated subnetworks based on multi-omics data with DeRegNet. BMC Bioinformatics 2022;23:139. [PMID: 35439941 DOI: 10.1186/s12859-022-04670-6] [Reference Citation Analysis]
131 Han HH, Tian H, Zang Y, Sedgwick AC, Li J, Sessler JL, He XP, James TD. Small-molecule fluorescence-based probes for interrogating major organ diseases. Chem Soc Rev 2021;50:9391-429. [PMID: 34232230 DOI: 10.1039/d0cs01183e] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]